What Leads Demonstrate the ST Depression

at
Categories
Tags

1. What Leads Demonstrate the ST Depression?
2. Is Lorene Hypertensive per ACA 2017 Guidelines? Compare the ACA guidelines to JNC 8 guidelines and discuss what treatment you recommend for her BP and why.
3. What is the Primary diagnosis causing Lorene’s chest pain? Include ICD 10 codes (no differentials)
4. What other secondary diagnoses does Lorene have that should be addressed? (Include the rationale and a reference for your diagnoses)
5. Design a treatment plan and discuss how each intervention is applicable to Lorene’s case. Consider the following interventions:
o Labs
o Durable Medical Equipment Diagnostic tests- discuss the goal/purpose
o Any consultation with outside providers/services
o Medications- discuss why you chose each specific medication
o Referrals- who and why

Sample Solution

What Leads Demonstrate the ST Depression

ST depression refers to a finding on an electrocardiogram, wherein the trace in the ST segment is abnormally low below the baseline. It is often a sign of myocardial ischemia, of which coronary insufficiency is a major cause. Other ischemic heart diseases causing ST depression include: subendocardial ischemia or even infarction. ST depression can be treated. Provided ST depression during treatment with B-blockers is correlated to myocardial ischemia in the same way as without such treatments used, other factors, such as increase in cardiac size, will contribute more to the ischemia. Labetalol may cause less increase in cardiac size than propranolol.

portrayed for the CYP2B6, also more than 100 SNPs have been described. Among various variants, the CYP2B6*6 haplotype (785 A > G, 516 G >T) give rise to reduction in the catalytic activity and a huge decrease in the expression of the protein. The frequency of the mutant allele, CYP2B6*6, varies among various ethnic groups: 25% in white persons, 15 to 40% in Asians, and more than half in black African and Africans Americans (Lang et al., 2001; Mehlotra et al., 2006). The CYP2B6*16 (785 A > G; 983 T > C) or the CYP2B6*18 (983 T > C) variations that are generally common in black populations, result in a decrease in the expression of the relating protein without influencing its intrinsic catalytic activities (Wang et al., 2006).

Efavirenz is mostly metabolized by CYP2B6 into 8-hydroxy efavirenz and less so throughout accessory pathways including CYP3A4/5, CYP2A6, and UGT2B7 (Ward et al., 2003; Desta et al., 2007). Additionally, efavirenz can induce its own metabolism as a self-inducer of CYP2B6 (Zhu et al., 2009). This self-induction might be specific for certain tissues that would also propose specific induction mechanism (Lee et al., 2006). In that capacity, the fractional metabolic clearance of efavirenz would be in charge of around 90% of its systemic clearance (Wardetal.,2003). Administration orally of adailydose of 600 mg of efavirenz is connected with wide inter-individual differences in plasma concentrations (Csajka et al., 2003).

Numerous studies have reported a relationship between genetic polymorphisms of CYP2B6 and the pharmacokinetics of efavirenz (Carr et al., 2010). Tsuchiya et al (2004) stated an increase in efavirenz plasma concentrations in CYP2B6*6/*6 people. An additional study demonstrated a relationship between the CYP2B6 516 G > T variation and A) increased intra-cellular concentrations of the medication in PBMCs (peripheral blood mononuclear cells), B) an increase in the area under the curve for efavirenz, and C) a higher toxicity risk in the CNS, central nervous system, of individuals homozygous for the allelic variation (Rotgeretal., 2005a). in 2006, Wang et al. demonstrated that the concentrations of efavirenz steady-state were higher in Africans that were carriers of the CYP2B6*16 allelic variation than in different patients (Wang et al., 2006).

Another study done by Cabrera et al (2009) built up a population pharmacokinetics mo

This question has been answered.

Get Answer